Kalaris Therapeutics, Inc.
KLRSNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$46.2M | −$51.7M | −$199.9M | −$171.2M | −$169.8M | −$71.3M |
| Net income | −$43.4M | −$69.2M | −$190.4M | −$168.7M | −$172.0M | −$69.8M |
| Total assets | $121.7M | $6.2M | $190.8M | $277.1M | $286.6M | $370.8M |
| Total liabilities | $42.9M | $56.8M | $45.0M | $52.6M | $61.3M | $17.8M |
| Equity | $78.8M | −$96.6M | −$45.0M | $224.5M | $225.3M | $353.1M |
| EPS (diluted) | $-2.85 | $-51.77 | $-42.09 | $-2.20 | $-2.74 | — |
| Shares out. | 5.0M | 114.9M | 93.5M | 65.3M | 65.1M | 61.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −55.1%
- Return on assets
- −35.7%
- Return on capital (ROCE)
- −41.2%
- Liabilities / assets
- 35.3%
- Debt / equity
- 0.54×
- Book value / share
- $15.63
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 0.97distress
- Accruals / assets
- −4.2%clean
- Piotroski F-Score
- 5/7mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Samsara Biocapital, L.P.Activist (13D)May 22, 2026
- Rtw Investments, LpPassive (13G)Feb 17, 2026
- Invus Global Management, LlcPassive (13G)Jul 29, 2025
- Ecor1 Capital, LlcPassive (13G)May 15, 2025
- Gilead Sciences, Inc.Passive (13G)Mar 20, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 804,374 | 7.9 | -0.2% |
| Apr 30, 2026 | 805,754 | 8.9 | -4.4% |
| Apr 15, 2026 | 842,687 | 9.5 | -15.3% |
| Mar 31, 2026 | 995,274 | 14.6 | +8.3% |
| Mar 13, 2026 | 919,448 | 19.6 | +2.5% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 12, 2026
- Director / officer changeApr 10, 2026
- Results of operationsMar 17, 2026
- Regulation FD disclosureMar 9, 2026
- Entered a material agreement · Unregistered equity sale · Other material eventDec 18, 2025
- Regulation FD disclosure · Other material eventDec 17, 2025
- Results of operationsNov 12, 2025
- Director / officer changeNov 3, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.